European Society of Cardiology Congress · Munich · 28–31 August 2026
What ESC 2026 actually changes in your clinic
Three rewritten guidelines, a new definition of myocardial infarction, and a handful of Hot Line trials that will show up in your next difficult conversation with a patient. Here's the digest — no 45-minute session replay required.
Heart failure gets a new vocabulary
The 2026 ESC Guidelines for the Management of Heart Failure replace the 2021 document outright — new evidence grading, new phenotypes, new stages, and a stated priority on catching disease before it becomes symptomatic.
Task force chair Lars Køber framed the rewrite around prevention: heart failure now spans four stages, from patients merely at risk (Stage A) to advanced disease (Stage D), rather than being described only once symptoms appear. The biggest change you'll notice at the point of care, though, is in how ejection fraction is categorized.
Recommendations were also updated for cardiac glycosides, durable mechanical circulatory support, and mitral transcatheter edge-to-edge repair, and the document leans harder on patient education and shared decision-making than its predecessor did.
Clinical bottom line
Anyone you've been carrying as HFmrEF (LVEF 41–49%) is now simply HFrEF — revisit their eligibility for foundational HFrEF therapy at the next visit. And HFpEF patients with obesity are now a reasonable, guideline-anchored conversation for a GLP-1 agent, not an off-label stretch.
Two more guidelines landed quietly alongside it
Heart failure took the headlines, but ESC also published its first-ever dedicated guidance on cardiac rehabilitation and on the cardiology–nephrology overlap — both filling real gaps.
Cardiac rehabilitation
Moves rehab well beyond post-MI and post-HF patients, extending formal recommendations to congenital heart disease, atrial fibrillation, valve replacement, and cancer-therapy-related cardiotoxicity — with guidance on staffing, delivery models, and outcome tracking for Phase II programs.
Cardiovascular disease & CKD
Developed with the European Renal Association, built around the "STAMP on CKD" framework. The headline ask: every patient with heart disease should be screened for kidney disease, and every clinician managing CVD should treat CKD as part of that same risk equation.
Clinical bottom line
If eGFR and urine albumin-to-creatinine ratio aren't already part of your routine CV workup, this is the guideline that says they should be — for essentially every patient walking through your door, not just diabetics.
A fifth definition of myocardial infarction
The long-standing numerical MI typology (Type 1 through Type 5) has been retired in favor of three clinical categories: primary, secondary, and procedure-related myocardial infarction.
The change is meant to make the diagnosis map more directly onto mechanism and management rather than a numbering system many clinicians never fully internalized. Expect this to filter into discharge summaries, coding, and registry data over the next year — and into a few "wait, which type was that again?" moments in the meantime.
Clinical bottom line
Start using primary / secondary / procedure-related language in your own documentation now — it'll be the shared vocabulary in trials and registries going forward.
The Hot Line trials worth knowing cold
Of the 59 late-breaking trials, four are the ones most likely to come up with patients or colleagues this year.
TRIC-I-HF
Transcatheter tricuspid valve repair (98% via edge-to-edge repair) added to optimal medical therapy beat medical therapy alone on both a one-year composite of death, HF hospitalization, and quality-of-life gain (win ratio 2.42), and on death or HF hospitalization through three years.
Why it matters: the first trial to show transcatheter tricuspid repair moves hard outcomes, not just how patients feel. Expect this to shape the next valve guideline update.
TAVI-PCI
Treating the valve before the coronaries (TAVI-first) was noninferior to the traditional PCI-first sequence, with numerically lower bleeding and acute kidney injury in the TAVI-first arm.
Why it matters: gives your heart team real latitude to sequence procedures around the patient in front of you rather than a fixed order.
CARDIO-TTRansform negative
Eplontersen did not significantly reduce cardiovascular mortality or recurrent cardiovascular events versus placebo across the overall trial population.
Why it matters: a reminder to hold the line on realistic expectations with amyloid patients until subgroup and mechanistic analyses are fully published.
SINGLE-AF
Direct oral anticoagulant therapy reduced adverse clinical events compared with no anticoagulation in AF patients at intermediate — not just high — stroke risk.
Why it matters: fills in the grey zone that's made intermediate-risk AF one of the more common judgment calls in clinic.
Still generating hallway debate, with data still being digested: REBOOT-PARADOX on revascularization strategy, NATURE on thrombectomy technique, SELUTION DeNovo on drug-coated balloons, and the paired TARGET FIRST / ULTIMATE DAPT studies on abbreviated antiplatelet regimens. Worth a closer look once the full manuscripts are out.
For Monday morning clinic
- Re-stage any patient labeled HFmrEF as HFrEF and check whether they're now eligible for foundational HFrEF therapy.
- Raise semaglutide or tirzepatide with HFpEF patients who also have obesity — it's now a Class IIa conversation, not an off-label one.
- Add eGFR and urine albumin-to-creatinine ratio to your standard CV workup, not just for patients with diabetes.
- Consider a structural referral for symptomatic severe tricuspid regurgitation with heart-failure-risk features — TRIC-I-HF gives you outcome data to back the conversation.
- Don't assume a fixed order for combined TAVI + PCI cases — sequencing can now reasonably follow the individual patient.
- Start writing primary / secondary / procedure-related MI into your documentation as the new shared language.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.